Background: Adiponectin expression and plasma concentrations are decreased in human and animal models of obesity. Several single nucleotide polymorphisms (SNPs) in the adiponectin gene are known to influence the plasmatic concentration of the encoded protein. Some of these adiponectin polymorphisms have been associated with BMI in cross-sectional studies. Objective: The aim of our study was to examine the longitudinal relationships between adiponectin gene polymorphisms and anthropometric indices. Design: Two adiponectin gene (ADIPOQ) SNPs, À11391G4A and À11377C4G, were genotyped in 837 French Caucasian subjects from the SUpplémentation en VItamines et Minéraux Anti-oXydants (SU.VI.MAX) cohort. Anthropometric scores were measured at three clinical examinations over a 7-year period. Results: For À11391G4A as well as for À11377C4G, we detected no association between the variant allele and anthropometric measurements at baseline. Considering longitudinal effects, we detected moderately higher waist-to-hip ratio (WHR) changes for the carriers of the À11391A (P ¼ 0.02) and À11377C (P ¼ 0.03) allele over the follow-up of the study. À11391G4A and À11377C4G define haplotypes associated also with WHR measurements and their changes over the followup of the study. Diploid configurations that combine À11391A and À11377C were associated with significantly higher WHR changes (DCE: P ¼ 0.02) compared to other haplotypes. In addition, higher adiponectin levels were observed in AC/AC diplotypes compared to GG/GG carriers (Po0.0001). Conclusion: In the SU.VI.MAX study, genetic variations in the adiponectin gene affect abdominal fat gain over life span.
Introduction
The current obesity epidemic is a major public health problem, as excess of body fat mass, particularly in the abdominal area, is an important risk factor for chronic diseases such as type 2 diabetes and cardiovascular diseases. 1 Adipose tissue is recognized as a secretory organ, which actively participates in a complex network of endocrine, paracrine and autocrine signalling pathways. 2 Adipose tissue-derived bioactive molecules influence energy homoeostasis, whole-body metabolism and inflammation and, when dysregulated may contribute to the development of obesity-related complications. 3 Adiponectin is an adipose cell-specific protein, whose expression and plasma concentrations are decreased in human and animal models of obesity. 4 The synthesis of this adipokine increases with weight loss. Plasma adiponectin concentrations are inversely correlated with the severity of insulin resistance in various clinical settings. 5, 6 Screening of the adiponectin-encoding adipocyte C1q and collagen-domain-containing (ADIPOQ) gene led to the discovery of genetic variations located in its coding and regulatory regions, and some of these variants associate with ADIPOQ gene expression and circulating concentrations of the protein. [7] [8] [9] [10] Polymorphisms in exon 2 of the ADIPOQ gene, 45G4T and 276T4G, have been associated with obesity and insulin resistance. 11, 12 Single nucleotide polymorphisms (SNPs) in the 5 0 region of the ADIPOQ gene, À11391G4A and À11377C4G, define haplotypes associated with diminished adiponectin concentrations and increased risk of type 2 diabetes in French Caucasians. 9 Since this risk of type 2 diabetes increases according to the level of corpulence, 9 the authors emphasized that adiponectin may represent a crucial link between the degree of obesity and the level of insulin resistance. These observations raised the question of the genetic contribution of ADIPOQ gene to body corpulence variation over the life span in the general population. We thus hypothesized that ADIPOQ gene SNPs located in the 5 0 gene region might represent markers associated with variation of body weight and fat mass distribution. To test this hypothesis, we investigated the relationships between À11391G4A (rs17300539) and À11377C4G (rs266729) ADIPOQ polymorphisms and BMI, waist circumference, WHR and their changes over the follow-up in middle-aged subjects from the SU.VI.MAX ('SUpplémentation en VItamines et Minéraux Anti-oXydants') study. We deliberately focussed our study on these two polymorphisms because of their demonstrated individual effects on the modulation of adiponectin plasma concentrations in several Caucasian populations.
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Subjects and methods
Subjects
Subjects were participants of the SU.VI.MAX study, a randomized, double-blind, placebo-controlled, primaryprevention trial designed to test the impact of a daily antioxidant supplementation (vitamin C, vitamin E, b-carotene, selenium, zinc) at nutritional doses on the incidence of cancers and ischaemic heart disease. 13 Details on the rationale, design, methods of the study and baseline characteristics of the subjects have been described elsewhere. 13, 14 Briefly, 13,017 subjects from all over France (5141 men aged 45-60 years, 7876 women aged 35-60 years), free of severe health problems, were included between October 1994 and June 1995. The follow-up period ended in September 2002. 14 All subjects gave their informed written consent to the study which was approved by the ethical committee for studies with human subjects of ParisCochin Hospital (CCPPRB no. 706), and the 'Commission Nationale de l'Informatique et des Libertés' (CNIL no. 334641), which advocates that all medical information remain confidential and anonymous. During the follow-up, participants were invited to three clinical examinations including anthropometric measurements. The first took place in 1995-1996 period (CE1), the second in 1998-1999 (CE2) and the third in . For the present study, only those subjects living in the Paris area (because of available DNA) and with available data for each measure of weight and height were included (n ¼ 1081). To detect putative genetic association between target SNPs and obesity-related phenotypes, we first screened SNPs in a random subsample of 167 men and 228 women, representative of the 1081 subjects. This subsample selection was stratified by sex, age (class of 5 years) and body weight change between the first and the last clinical examination (9 classes: À10 kg and more, from À10 to À5 kg, from À5 to À3 kg, from À3 to À1 kg, from À1 to þ 1 kg, from þ 1 to þ 3 kg, from þ 3 to þ 5 kg, from þ 5 to þ 10 kg, þ 10 kg and more). To increase statistical power and eventually confirm our preliminary results, we extended our screening to the entire group initially selected. Subjects following a lipid, diabetes or obese treatments were excluded from the study (n ¼ 244). Therefore, analyses in the present report were based on data from 837 subjects (323 men and 514 women). Characteristics of these subjects are presented in Table 1 .
Anthropometric measurements
Weight, height, hip and waist circumferences were measured using standardized procedures. Weight was measured using an electronic scale with subjects in indoor clothing and no shoes. Height was measured in the same conditions to the nearest 0.5 cm with a wall-mounted stadiometer. Body Mass Index (BMI) was calculated as weight divided by height squared (kg m
À2
). Using an inelastic tape, waist girth was measured as the circumference midway between lower ribs and iliac crests, and hip girth was measured as the largest circumference between waist and thighs, both in standing position, by the same clinical investigator. Waist-to-hip ratio (WHR) was obtained in dividing waist girth (cm) by hip circumference (cm). Adiponectin gene and weight gain G Dolley et al BMI was considered as an indicator of overall corpulence or adiposity, waist circumference as an indicator of abdominal fat accumulation, and WHR as an indicator of body fat repartition (upper versus lower body fat). 15 Adiponectin level measurements Adiponectin concentrations were measured according to the ADIPOQ AC/AC and GG/GG haplotypes. Because of limited serum, only 35 GG/GG and 9 AC/AC subjects were evaluated for adiponectin levels. Blood samples were obtained at CE1 after a 12-h fast, and all biochemical measurements were centralized. Serum adiponectin levels were determined using radioimmunoassay kit from Linco Research (St Louis, MI, USA) according to the manufacturer's recommendation. A human standard was provided by the manufacturer as two quality control samples. The sensitivity of these assays was 0.8 ng ml À1 for adiponectin.
Gene screening DNA was extracted from ethylenediaminetetraacetic acid (EDTA) whole blood samples using the Puregen kit (Gentre, Minneapolis, MI, USA). Polymorphisms were genotyped using LightCycler apparatus (Roche Diagnostics, Meylan, France) and hybridization probes. Design of primers and probes were carried out by TIB MOLBIOL (Berlin, Germany). The PCR reaction contained 20 ng of DNA, 1X Fast Start DNA master hybridization probes, 3 mM MgCl 2 , 0.5 mM of primers, 0.15 mM of probes in 10 ml total volume. Sequences of primers were sense, 5 0 -TGTTGAAGTTGGTGCTGGCAT, antisense, 5 0 -AGCCTGGAGAACTGGAAGCT. And sequences of hybridization probes were anchor, GCAAGCCACACATTCTGATGAA TZTAAATTACGACCC, sensor, TGAAGCGCAGGATCTGAGC CGGTTC. Annealing temperature for ADIPOQ was 60 1C, PCR amplification was carried out according to the manufacturer's instructions. SNP genotyping was carried out using melting curves analysis. For ADIPOQ À11391G4A and ADIPOQ À11377C4G only one hybridization probe was used. RFLP using HhaI for ADIPOQ À11377C4G and HpaII for ADIPOQ À11391G4A were used to define controls for melting curves profile for all polymorphism combinations. Genotypes were obtained in 100% of the subjects.
Test for population stratification
Ninety-six SNPs randomly distributed over the genome were analysed. SNPs were genotyped using an oligo-ligation assay (SNPlex, Applied Biosystems, Foster City, CA, USA) following the manufacturer's guidelines. Allele specific SNPlex probes were designed (Applied Biosysytems). Up to 48 SNPs can thus be multiplexed into one oligo-ligation reaction. Forty nanograms of genomic DNA was heat fragmented. Phosphorylated probes were added, the DNA denatured at 90 1C for 3 min and the oligo-ligation assay performed on a PE 9700 thermal cycler following the manufacturer's protocol with 30 cycles of 90 1C for 15 s, 60 1C for 30 s and 51 1C for 30 s, followed by a denaturation step at 99 1C for 10 min to recover ligation products. After washing and subsequent denaturation at 95 1C for 10 min, the ligation products were amplified by PCR for 30 cycles at 95 1C for 15 s and an annealing/amplification step at 70 1C for 60 s using biotynylated primers. Amplification products were recovered in a strepavidin coated plate and hybridized with the allele specific ZIPchute probe. Plates were washed and SNPlex sample loading reagent was added to the plates and the allele specific fluorescent probes separated on an automated sequencer (ABI 3730, Applied Biosystems). Alleles were binned and identified using the GeneMapper software (Applied Biosystems).
Stratification analysis
The STRUCTURE software package (http://www.stats.ox. ac.uk/~pritch/home/html) was used to examine the SU.VI. MAX population for possible stratification. This program is based on a model based clustering method to examine genotype data at multiple independent loci to detect population substructures. 16 Statistical analysis A w 2 -test was applied to assess whether genotype and allele frequencies were in Hardy-Weinberg equilibrium. Genetic associations were assessed by analysis of covariance comparing mean anthropometric and adiponectin measurement values across ADIPOQ genotypes or haplotypes. For quantitative continuous phenotypic variables, the least square means (LSMEANS) procedure was used to detect significant differences between groups. Before analysis, variables that were not normally distributed were mathematically transformed by square root or log 10 to achieve normalization. Reported least-squares ± s.d. are for untransformed variables, while P-values are for transformed scores when applicable. Phenotypes were adjusted for age, sex and with or without adjustment for BMI. To determine longitudinal effect of ADIPOQ SNPs, the follow-up subtraction of CE3 (2001-2202) from CE1 (1995-1996) measurements was performed. The resulting delta scores were adjusted for age and sex. In addition, we adjusted the delta scores for the value at baseline in order to reduce the phenomenon of regression towards the mean. Correlation analyses were performed using Pearson's test. All statistical analyses were performed with the SAS statistical package (version 8.02) using a P-value threshold of 0.05.
Results
Population stratification can lead to false positive associations using case/control studies. It was therefore verified that the SU.VI.MAX samples used in this study did not show any Adiponectin gene and weight gain G Dolley et al inherent allele frequency differences. Two panels of SNPs (96 SNPs in total) randomly distributed over the entire genome were genotyped and analysed using the STRUCTURE program. The results showed that no significant differences in allele frequencies were observed within the SU.VI.MAX population (data not shown).
The SU.VI.MAX study included placebo and subjects controlled for daily vitamin supplementation. We tested if this intervention could modify the results of the genetic association study. Since we observed similar results irrespective of whether a subject received vitamin supplementation or not, we presented our results without this adjustment.
In the present study, the allelic frequencies for À11391G4A and À11377C4G ADIPOQ polymorphisms were 0.11 and 0.23 respectively. The genotype distributions were in Hardy-Weinberg equilibrium. There were not differences in frequencies between males and females (data not shown).
The first screening applied to a subset of 395 subjects revealed significant associations between the À11391G4A polymorphism and BMI at baseline, while the À11377C4G SNP was associated with BMI and WHR changes (data not shown). This prompted us to extend our investigation to the whole group of 837 subjects. In the extended population we found no significant associations between À11391G4A SNP and BMI. However, higher waist girth (P ¼ 0.04) and WHR (P ¼ 0.02) were observed for the carriers of the À11391A allele at CE3. Moreover, waist girth and WHR changes over the follow-up (between CE1 and CE3) were consistently higher in these subjects, when compared to the GG homozygote carriers (P ¼ 0.03 and P ¼ 0.02, respectively) ( Table 2) .
No association was found between À11377C4G SNP and any of the corpulence-related phenotypes at the three CEs. However, the subjects carrying the -11377C allele presented a slight increase of WHR between CE1 and CE3 (P ¼ 0.03) ( Table 3) .
Because adiponectin levels differ between men and women, we investigated the effects of SNP on weight gain in a gender-stratified analysis. The association pattern was slightly different between men and women. For example, women (n ¼ 514) carrying the À11391A allele showed higher waist girth at the end of the study (CE3) (79.3 vs 76.6 cm for À11391GG; P ¼ 0.02). A significant difference in D waist girth (CE3-CE1) was also found for women (3.42 vs 2.26 cm for À11391GG; P ¼ 0.05) while a trend was observed for WHR values (not shown). Among men (n ¼ 323), similar phenotype differences were observed between genotype groups but did not reach statistical significance (data not shown).
We finally examined the effects of ADIPOQ SNP combination on BMI, waist and WHR in the whole cohort to maximize the power. In agreement with previous studies, 5 we found a standardized linkage disequilibrium between À11391 and À11377 SNPs (D 0 ¼ 0.997, Po0.0001; r 2 ¼ 0.036).
We then constructed haplotypes using these two SNPs for each subject, thus providing a diploid configuration. No associations were found between the diploid configurations and the anthropometric variables at CE1 (Table 4) . Considering the longitudinal effects, we found a significant variation in change of WHR between CE1 and CE3. The haplotype combination of -11391A and -11377C (A_C/A_C and G_C/A_C) had a significant effect on raising D WHR, when compared to the GG haplotype. This difference was Adiponectin gene and weight gain G Dolley et al maximal between AC/AC and GG/GG diplotypes (P ¼ 0.008). We hypothesized that the observed association could be associated with differences in adiponectin levels in adiponectin gene variant carriers. Therefore, we measured adiponectin concentrations on the ADIPOQ AC/AC and GG/GG haplotypes (n ¼ 44) carriers and assessed the relationships between these subjects and adiponectin serum levels. As shown in Figure 1 , AC/AC subjects had significantly higher adiponectin serum concentrations than GG/GG carriers (Po0.0001). Associations with changes in WHR were also tested in this subgroup of 44 subjects. According to Table 4 , AC/AC subjects had significantly greater D WHR (data not shown). Interestingly, this association did not remain significant when adjusted for adiponectin levels. In addition, positives correlations between adiponectin levels at CE1 and D WHR (Pearson: r ¼ 0.33; P ¼ 0.04) were observed. This result was obtain with Pearson's test and was adjusted for the effect of age, sex and the value of WHR at baseline. Spearman's test provides similar results (data not shown).
Discussion
The discovery of the adiponectin protein and its potential role in metabolic disorders led us to consider the role of ADIPOQ as a candidate gene for body corpulence change over time. 17 We assessed the impact of two common ADIPOQ variants (located in the 5 0 region) on corpulence and body fat distribution in a large cohort of 837 unrelated middle-aged French subjects that were prospectively followed up for 7 years.
In this cohort, frequencies for both the À11391G4A and the À11377C4G polymorphisms were in Hardy-Weinberg equilibrium and agreed with results previously found in Caucasians. 9, 10 In addition, by testing this population for a wide panel of polymorphisms, we confirmed the absence of a population substructure in the SU.VI.MAX cohort. We report here that the À11391G4A polymorphism was moderately associated with changes in WHR during a followup study of the SU.VI.MAX population, but not with BMI change. In addition, the À11391A allele was associated with a higher waist circumference during the 7-year follow-up as well as at CE3, which suggests that this marker could be implicated in abdominal body fat gain. In contrast to this polymorphism, the -11377C4G SNP was associated with decreased means of WHR over the follow-up of the study.
According to previous studies 9, 18, 19 we found standardized linkage disequilibrium between À11391 and À11377 SNPs. In this context, haplotype combinations could clarify associations involving these correlated markers. Further analyses were performed with haplotypes of the À11391 and À11377 SNPs. In agreement with SNPs tested individually, the diploid configuration that combines À11391A and À11377C alleles was associated with higher WHR changes in the follow-up period, which led to WHR differences at CE3 (data not shown). Some studies found that the area covered by visceral fat, a key factor associated with a higher risk of obesity and cardiovascular complications, was a significant determinant of serum adiponectin concentrations. 20, 21 Berthier et al. 7 demonstrated that the presence of visceral adipose tissue modulates the contribution of two other SNPs, c.45T4G and c.276G4T in the coding region of the ADIPOQ gene, on plasma adiponectin concentrations. The present association study suggests that À11391A and À11377C carriers of 5 0 ADIPOQ gene variants could be prone to a higher regional fat increase over time in a general population. In contrast, Fumeron et al. 22 found no association between the Adiponectin gene and weight gain G Dolley et al À11391G4A SNP and WHR at baseline and during the 3-year follow-up in their study in a population survey.
The physiological mechanisms behind our genetic findings could be attributed to the effect of the ADIPOQ promoter SNPs on adiponectin levels. Our results indicate that alleles implicated in body fat gain were also associated with higher adiponectin concentrations. In addition, further adjustment for adiponectin levels diminished the haplotype-DWHR association. This result suggests that the increases of adiponectin levels caused by ADIPOQ polymorphisms are responsible for the association. Despite the low number of subjects measured for adiponectin levels, our results were in close agreement with other studies. [8] [9] [10] 18, 19 It has been previously described in different obese and nonobese populations that plasma concentrations of adiponectin are significantly higher in À11391A allele carriers, while À11377C4G ADIPOQ polymorphism induced lower adiponectin levels. Furthermore, transcriptional activity of the ADIPOQ promoter, measured with a luciferase assay, demonstrated that the À11391G4A polymorphism had a 2.5-fold increase in transcriptional activity, which was in accordance with higher adiponectin levels observed in À11391A carriers. 18 In the same order of idea, our results show positive correlation between adiponectin levels and weight gain. Thus, a high level of adiponectin concentration is predictive to weight gain over the years. However, the evolution of adiponectin levels over the follow-up cannot be observed while no adiponectin measurement was available at CE3. Adiponectin biological activity involves the facilitation of fatty acid transport and oxidation by CD36, UCP2 and PPARg via AMPK activation; 23, 24 and thus promotes lipid utilization and decreases fat storage (especially in the visceral adipose tissue). 4, [25] [26] [27] Decreased adiponectin levels were described in weight-stable obese subjects. However, many studies have reported an association between obesity risk and hyperadiponectinemia associated with polymorphisms, 9,18,28 which were in accordance with our results. The physiological mechanisms to explain these results are a complex question to address. Bouatia-Naji et al. 18 suggested the physiological contribution of adiponectin to weight gain over time may be mediated by its insulin-sensitizing action in adipose tissue. Indeed, Fu et al.
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suggested a new role for adiponectin as a factor augmenting programmed gene expression responsible for adipogenesis (that is, PPARg) and increasing lipid content and insulin responsiveness of the glucose transport system in adipocytes.
In conclusion, ADIPOQ gene promoter SNPs are moderately associated with development of abdominal corpulence over the 7-year follow-up, suggesting a putative role of adiponectin in body fat gain in the general population.
